NCT05206591View on ClinicalTrials.gov

Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 16, 2022

Primary Completion Date

March 20, 2028

Study Completion Date

June 12, 2028

Conditions
Active Peripheral Spondyloarthritis (pSpA)
Interventions
BIOLOGICAL

Secukinumab

Secukinumab 300 s.c.

OTHER

Placebo

Placebo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY